会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 24. 发明授权
    • Azacyclic compounds and their use as analgesic agents
    • 氮环化合物及其作为止痛剂的用途
    • US4994450A
    • 1991-02-19
    • US309687
    • 1989-02-10
    • Vittorio VecchiettiAntonio Giordani
    • Vittorio VecchiettiAntonio Giordani
    • C07D223/04A61K31/4433A61K31/445A61K31/451A61K31/55A61P25/04C07D211/26C07D225/02C07D409/06
    • C07D409/06C07D211/26
    • A compound, or a solvate or salt thereof, of formula (I) ##STR1## in which: R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl or C.sub.4-12 cycloalkylalkyl groups, or together form a C.sub.2-8 branched or linear polymethylene or C.sub.2-6 alkenylene group optionally substituted with a hetero-atom, provided that R.sub.1 and R.sub.2 are not simultaneously hydrogen;R.sub.3 is hydrogen, C.sub.1-6 alkyl, preferably methyl or ethyl, or phenyl, or R.sub.3 together with R.sub.1 form a --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 -- group;p is 1, 2, 3 or 4, andR is a group of formula (II) ##STR2## in which the group --(CHR.sub.4).sub.n --X-- is in the meta- or para-position with respect to YR.sub.5 or R.sub.6, R.sub.4 is hydrogen or C.sub.1-6 alkyl, preferably hydrogen;n is 0, 1 or 2, preferably 1;X is a direct bond, or O, S or NR.sub.a in which R.sub.a is hydrogen or C.sub.1-6 alkyl, and is preferably a direct bond;Y is >C.dbd.O, >CHOH, --S.dbd.O or --SO.sub.2 ; each of R.sub.5 and R.sub.6 is C.sub.1-6 alkyl, orR.sub.5 and R.sub.6 are linked together and R.sub.5 represents --(Z).sub.m -- where m is 0 or 1 and Z is O, S or NR.sub.7 where R.sub.7 is hydrogen or C.sub.1-6 alkyl, andR.sub.6 represents --(CH.sub.2).sub.9 -- where q is an integer of from 1 to 4, preferably 2 or 3, and in which one or more of the --(CH.sub.2)-- groups is optionally substituted by a C.sub.1-6 alkyl group, is useful for the treatment of pain.
    • 27. 发明申请
    • 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors
    • 1,5-二芳基-2-烷基吡咯-3-取代的硝基酯,选择性COX-2抑制剂和一氧化氮供体
    • US20130165494A1
    • 2013-06-27
    • US13820533
    • 2011-09-07
    • Antonio GiordaniMariangela BiavaMaurizio AnziniVicenzo CalderoneLucio Claudio Rovati
    • Antonio GiordaniMariangela BiavaMaurizio AnziniVicenzo CalderoneLucio Claudio Rovati
    • C07D207/337A61K45/00A61K31/40
    • C07D207/337A61K31/40A61K45/00C07D207/333C07D207/335Y02A50/473
    • 1,5-diaryl-2-alkylpyrrole-3-substituted nitro esters, of Formula (I) are provided. Such compounds are potent and selective COX-2 inhibitors which are able to release NO in concentrations that make it possible to counteract the side effects due to selective COX-2 inhibition, without giving rise to hypotensive effects. Formula (I) includes compounds wherein the groups R′ and R″ are: —H, —F, —Cl, —Br, —CH3, —CF3, —OCH3, —SCH3, R1 is methyl, ethyl, trifluoromethyl, hydroxymethyl, methoxymethyl and the substituent in position −3 of the pyrrole ring is a chain, where the groups X, Y, Z, W and R2 are: X is a carbonyl or a group —(CHR3)—, Y is an oxygen atom or the group —NR3— and Z is a carbonyl or a group —(CHR3)—, or a [—CH(COOH)—] group, or a group —(NR3)—, W is an aliphatic chain substituted with one or two (—O—NO2) groups, R2 is: —H, —OH, —OCH3, or —NHR3. R3 is: —H, —CH3, —CH2CH3, [—CH2(CH3)2]. R′″ is methylsulphonyl or sulphonamido. Pharmaceutical formulations and methods of making an using such formulations are also provided.
    • 提供式(I)的1,5-二芳基-2-烷基吡咯-3-取代的硝基酯。 这些化合物是能够释放NO的有效和选择性COX-2抑制剂,其浓度可以抵消由于选择性COX-2抑制引起的副作用,而不会引起降血压作用。 式(I)包括其中基团R'和R“为:-H,-F,-Cl,-Br,-CH 3,-CF 3,-OCH 3,-SCH 3,R 1为甲基,乙基,三氟甲基,羟甲基 ,甲氧基甲基和吡咯环位置-3的取代基是一个链,其中基团X,Y,Z,W和R 2是:X是羰基或基团 - (CHR 3) - ,Y是氧原子或 基团-NR 3 - 和Z是羰基或 - (CHR 3) - 或[-CH(COOH) - ]基团或 - (NR 3) - 基团,W是被一个或两个 (-O-NO 2)基团,R 2是:-H,-OH,-OCH 3或-NHR 3。 R3是:-H,-CH3,-CH2CH3,[-CH2(CH3)2]。 R“'是甲基磺酰基或磺酰胺基。 还提供了制备使用这些制剂的药物制剂和方法。